Guardion Health Sciences ...
3.22
null (null%)
At close: Jan 14, 2025, 8:00 PM

Company Description

Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States.

It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices.

The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma.

It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing.

In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand.

Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com.

Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.

Guardion Health Sciences Inc.
Guardion Health Sciences Inc. logo
Country United States
IPO Date Apr 5, 2019
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 9
CEO Mark Goldstone

Contact Details

Address:
15150 Avenue of Science
San Diego, California
United States
Website https://www.guardionhealth.com

Stock Details

Ticker Symbol GHSI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001642375
CUSIP Number 40145Q203
ISIN Number US40145Q5009
Employer ID 47-4428421
SIC Code 2834

Key Executives

Name Position
Mark Goldstone Interim President, Chief Executive Officer & Director
Katie Cox Chief Accounting Officer
Robert Neal Weingarten Independent Chairman & Secretary

Latest SEC Filings

Date Type Title
Dec 26, 2024 8-K Current Report
Nov 18, 2024 8-K Current Report
Nov 08, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 31, 2024 8-K Current Report
Oct 11, 2024 25 Filing
Oct 03, 2024 8-K Current Report
Sep 23, 2024 8-K Current Report
Aug 28, 2024 4 Filing
Aug 28, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 21, 2024 8-K Current Report